Related Experiment Video

Updated: Jul 27, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

Effect of apolipoprotein polymorphisms in renal transplant recipients

M Cofan1, F Cofan, B Campos

  • 1Renal Transplant Unit, Hospital Clinic, University of Barcelona, Barcelona, Spain.

Transplantation Proceedings
|September 10, 2003
PubMed

Insights

Genetic variations in apolipoproteins did not significantly impact long-term renal transplant outcomes. This study found no correlation between apolipoprotein genotypes and patient or graft survival in renal transplant recipients.

Area of Science:

  • Nephrology
  • Genetics
  • Cardiology

Background:

  • Cardiovascular disease (CVD) is the leading cause of mortality in long-term renal transplant recipients (RTR).
  • Allograft chronic nephropathy is the primary cause of graft loss in long-term RTR.
  • Hyperlipidemia is a known risk factor for both CVD and graft loss, and apolipoprotein gene polymorphisms can influence lipid metabolism.

Purpose of the Study:

  • To investigate the association between apolipoprotein A-I, A-IV, and C-III gene polymorphisms and long-term renal transplantation outcomes.
  • To evaluate the impact of these genetic variations on renal allograft and patient survival.

Main Methods:

  • Genotyping was performed for apolipoprotein A-I (+83C/T), apolipoprotein C-III (Sst I), and apolipoprotein A-IV (Thr347Ser and Gln360His) polymorphisms in 516 kidney transplant patients.
  • Clinical data, including renal allograft and patient survival, were assessed over a 12-month period.
  • The distribution of specific genotypes for each polymorphism was recorded.

Main Results:

  • The study determined the frequencies of various genotypes for apo A-I, apo C-III, and apo A-IV polymorphisms.
  • No statistically significant differences were observed in the frequencies of these polymorphisms between genders.
  • Crucially, no significant influence of the evaluated apolipoprotein polymorphisms on renal allograft or patient survival was detected.

Conclusions:

  • Apolipoprotein gene polymorphisms (apo A-I, apo A-IV, apo C-III) do not appear to be significant predictors of long-term renal transplantation success.
  • Further research may be needed to explore other genetic or environmental factors influencing outcomes in renal transplant recipients.

More Related Videos

Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis07:05

Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis

Published on: May 17, 2015

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform07:13

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

Related Concept Videos

Factors Affecting Renal Clearance: Renal Impairment01:17

Factors Affecting Renal Clearance: Renal Impairment

Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...